ERBB2 and breast cancer: In breast cancer and other malignancies, high baseline NLR correlates with aggressive tumor behavior, increased metastatic potential, and poorer survival outcomes [[23], [24], [25], [26], [27], [28]], especially in luminal A and HER2-negative subtypes [29].